A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
Biotech ETF Index Surges 10% After Rebalance
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
Definium Therapeutics, Inc. Announces Proposed Public Offering
Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy
Definium Therapeutics, Inc. (DFTX) Shareholder/Analyst Call Transcript
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Definium Therapeutics, Inc. (DFTX) Analyst/Investor Day Transcript
These 3 Psychedelic Stocks Activated After Trump's Executive Order
Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
Definium Therapeutics (DFTX) Stock Gains After Hours: Here's What's Driving The Move
Definium Therapeutics Announces New Employee Inducement Grants
How Trump's psychedelics executive order could unlock stalled cannabis reform
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar
Psychedelics stocks rise after Trump order expands research, access pathways
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Rating of “Buy” by Analysts
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
Definium Therapeutics Teases 3 Key DT-120 Data Readouts This Year, Highlights De-Risked Phase 3 Design
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
Definium Therapeutics to Participate at Upcoming Investor Conferences
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages
Definium Therapeutics Announces New Employee Inducement Grants
Here Are Friday’s Top Wall Street Analyst Research Calls: Broadcom, Circle Internet, Kenvue, Medtronic, Sandisk, Southwest Airlines, Spotify, and More
Definium Therapeutics Appoints Roger Adsett to Board of Directors